Pharma lobbies for longer data protection periods

Pharmaceutical brand name corporations are pushing hard so that the revised EU legislation provides for prolongation of "data protection" and "commercial exclusivity" for their products.

You’ll find Medicines in Europe Forum position on this issue in the attached PDF.

 For more information click here.

Related EPHA articles

 Accession Countries issue declaration on EU pharma review

 European pharmaceutical association makes its case to EPHA